Program
SAL0137
A development code. Also written as “SAL0137 Dose 1”, “SAL0137 Dose 2” and “SAL0137 Dose 3”.
Its studies are mostly in Atherosclerosis, led by Shenzhen Salubris Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 11 open or running | phase 2since Jul 22, 2026 | Jul 22, 2026 | Dec 12, 2026phase 2 · NCT07729475 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2026First study: phase 2 study in AtherosclerosisFirst studyNCT07729475 · 120 planned · China
Ahead
- Dec 12, 2026Primary completion: phase 2 study in AtherosclerosisNCT07729475
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07729475Atherosclerosis · China | 2 | Not yet recruiting | Dec 12, 2026 | 120 |
How it is read
Names in the registry
- “SAL0137 Dose 1”, 1 entry
- “SAL0137 Dose 2”, 1 entry
- “SAL0137 Dose 3”, 1 entry
Codes read as this program: SAL0137.
Conditions, from the studies’ own filings
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.